A previous human trial with selenized yeast showed that selenium supplementation significantly reduced the incidence of lung, colon and prostate cancers. An intervention trial using cancer morbidity as the endpoint takes a long time to complete and is very costly. Surrogate intermediate endpoints or biomarkers are therefore needed to evaluate the efficacy of intervention. Our goal in the near future is to plan for a breast trial; a viable approach will be to use selenium-responsive biomarkers which are associated with the molecular mechanism of selenium chemoprevention. The MCF10AT and SUM-190PT human breast cell lines will be used for the proposed research. Upon transplantation, the MCF 10AT cells are able to develop a spectrum of dysplasia that recapitulate the pathology of human proliferative breast disease. Thus this cell line provides an ideal paradigm for studying selenium chemoprevention of high-risk lesions. The SUM-190PT cell line, on the other hand, exhibits amplification and over-expression of two known breast cancer oncogenes: erbB2 and cyclin D1. It harbors a genotype which is very close to that of human breast cancer.
Aim 1 will use the Affymetrix GeneChip to identify selenium-responsive biomarkers in human breast cells in an in vitro system. A detailed correlation between the temporal pattern of gene expression changes with distinctive biological outcome would provide important insight into the molecular mechanism of selenium chemoprevention. The modulation of gene products will be confirmed by semi-quantitative RT-PCR and/or Western analysis.
Aim 2 will investigate the functional significance of GADD153 in selenium control of cell proliferation and induction of apoptosis. This is a follow-up mechanism study based on our preliminary finding.
Aim 3 will verify the expression of the most sensitive biomarkers in a human breast cell xenograft model using SCID mice. Companion studies will be designed to determine the ability of selenium to inhibit the pathologic progression of the xenograft (atypical ductal hyperplasia to ductal carcinoma in situ to invasive carcinoma). The chemoprevention component of the research is an integral part of the biomarker project because it is imperative to assess the biological relevance of the biomarkers as prognostic indicators of breast cancer protection.
Aim 4 will study the effect of selenium on the biology and molecular biology of premalignant lesions in the mammary gland of rats treated with a carcinogen. The goal is to broaden our understanding of the significance of clonal suppression of early transformed cells in selenium protection of cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
1R01CA091990-01A1
Application #
6469106
Study Section
Metabolic Pathology Study Section (MEP)
Program Officer
Wang, Wendy
Project Start
2002-04-01
Project End
2007-03-31
Budget Start
2002-04-01
Budget End
2003-03-31
Support Year
1
Fiscal Year
2002
Total Cost
$346,382
Indirect Cost
Name
Roswell Park Cancer Institute Corp
Department
Type
DUNS #
City
Buffalo
State
NY
Country
United States
Zip Code
14263
Li, Song; Zhou, Yunfei; Dong, Yan et al. (2007) Doxorubicin and selenium cooperatively induce fas signaling in the absence of Fas/Fas ligand interaction. Anticancer Res 27:3075-82
Li, Song; Zhou, Yunfei; Wang, Ruiwen et al. (2007) Selenium sensitizes MCF-7 breast cancer cells to doxorubicin-induced apoptosis through modulation of phospho-Akt and its downstream substrates. Mol Cancer Ther 6:1031-8
Wu, Yue; Zu, Ke; Warren, Mary Ann et al. (2006) Delineating the mechanism by which selenium deactivates Akt in prostate cancer cells. Mol Cancer Ther 5:246-52
Shah, Yatrik M; Kaul, Aparna; Dong, Yan et al. (2005) Attenuation of estrogen receptor alpha (ERalpha) signaling by selenium in breast cancer cells via downregulation of ERalpha gene expression. Breast Cancer Res Treat 92:239-50
Shah, Yatrik M; Al-Dhaheri, Mariam; Dong, Yan et al. (2005) Selenium disrupts estrogen receptor (alpha) signaling and potentiates tamoxifen antagonism in endometrial cancer cells and tamoxifen-resistant breast cancer cells. Mol Cancer Ther 4:1239-49
Dong, Yan; Zhang, Haitao; Gao, Allen C et al. (2005) Androgen receptor signaling intensity is a key factor in determining the sensitivity of prostate cancer cells to selenium inhibition of growth and cancer-specific biomarkers. Mol Cancer Ther 4:1047-55
Zu, Ke; Hawthorn, Lesleyann; Ip, Clement (2005) Up-regulation of c-Jun-NH2-kinase pathway contributes to the induction of mitochondria-mediated apoptosis by alpha-tocopheryl succinate in human prostate cancer cells. Mol Cancer Ther 4:43-50
Zhang, Haitao; Dong, Yan; Zhao, Hongjuan et al. (2005) Microarray Data Mining for Potential Selenium Targets in Chemoprevention of Prostate Cancer. Cancer Genomics Proteomics 2:97-114
Cho, Sung Dae; Jiang, Cheng; Malewicz, Barbara et al. (2004) Methyl selenium metabolites decrease prostate-specific antigen expression by inducing protein degradation and suppressing androgen-stimulated transcription. Mol Cancer Ther 3:605-11
Dong, Yan; Lee, Soo Ok; Zhang, Haitao et al. (2004) Prostate specific antigen expression is down-regulated by selenium through disruption of androgen receptor signaling. Cancer Res 64:19-22

Showing the most recent 10 out of 13 publications